| Product Name | Nelfinavir mesylate |
|---|---|
| Description | Nelfinavir, also known as AG 1343, is a potent human immunodeficiency virus (HIV)-1 protease inhibitor with a Ki of 2 nM in vitro. Nelfinavir also displays broad spectrum anticancer activity and can inhibit the growth of cancer cells and trigger apoptosis. Nelfinavir has two main mechanisms of cancer cell growth inhibition, inhibition of the Akt/PKB signaling pathway and activation of endoplasmic reticulum stress with subsequent unfolded protein response. Nelfinavir also displays efficacy against malaria, tuberculosis and SARS and exhibits anti-MERS-CoV activity in vero cells in vitro. |
| Synonyms | AG 1343 |
| Molecular Weight | 663.9 Da |
| Target | Kinases,Other proteases,Antivirals |
| Amino Acid Sequence | (3S,4aS,8aS)-N-(1,1-Dimethylethyl)decahydro-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy- 2-methylbenzoyl)amino]-4-(phenylthio)butyl]-3-isoquinolinecarboxamide methanesulfonate |
| Form | White powder |
| Purity | >98% by hplc; NMR conforms to structure |
| Cas Number | 159989-65-8 |
| Storage | Store dessicated, frozen and in the dark |
| References |
Patick et al (1996) Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob.Agents Chemother. 40 29 PMID: 8787874Gills et al (2007) Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy and apoptosis in vitro and in vivo. Clin.Cancer Res. 13 5183 PMID: 17785575Ko et al (2020) Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South Korea identifies potential therapeutic options for COVID-19. BioRxiv 2020.02.25.965582 PMID: 33918958 Related areas All small molecules >All antiviral agents >All cancer research categories > |
| Supplier | Isca Biochemicals Limited |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
